Ilyang Pharm (007570) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.009x

Based on the latest financial reports, Ilyang Pharm (007570) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ilyang Pharm market capitalisation for the company's overall valuation and market capitalisation.

Ilyang Pharm - Cash Flow Conversion Efficiency Trend (2003–2024)

This chart illustrates how Ilyang Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ilyang Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharm ranked by their cash flow conversion efficiency. Explore earnings quality score of Ilyang Pharm to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Mukka Proteins Limited NSE:MUKKA	-0.019x
Torque Metals Ltd AU:TOR	-0.008x
Shanghai Bailian Group Co Ltd B SHG:900923	-0.046x
Cumberland Pharmaceuticals Inc NASDAQ:CPIX	0.010x
Ubiquoss Inc KQ:264450	-0.022x
TDM Berhad KLSE:2054	0.043x
Kalray SA PA:ALKAL	0.230x
Garuda Indonesia Persero Tbk JK:GIAA	-0.041x

Annual Cash Flow Conversion Efficiency for Ilyang Pharm (2003–2024)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharm from 2003 to 2024. View today's stock price for Ilyang Pharm for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩241.58 Billion ≈ $163.71 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-65.79%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩13.34 Billion ≈ $9.04 Million	0.068x	-33.76%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	+714.91%
2013-12-31	₩183.88 Billion ≈ $124.61 Million	₩-3.04 Billion ≈ $-2.06 Million	-0.017x	-112.63%
2003-12-31	₩77.13 Billion ≈ $52.27 Million	₩10.08 Billion ≈ $6.83 Million	0.131x	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$101.67 Million

₩150.03 Billion KRW

Market Cap Rank

#19238 Global

#947 in Korea

Share Price

₩8370.00

Change (1 day)

+0.12%

52-Week Range

₩7860.00 - ₩13160.00

All Time High

₩95982.23